Cantor Fitzgerald initiated coverage of eFfector Therapeutics (EFTR) with an Overweight rating and $50 price target.
The firm believes eFfector’s pipeline is underappreciated and thinks pipeline advancements will move the stock higher.
Wolfe Research initiated coverage of Tyler Technologies (TYL) with an Outperform rating and $550 price target. The firm sees improving demand trends in the market for Tyler coupled with an accelerating shift to the cloud. The firm would be buying the shares at current levels.